A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

NCT07085104 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus (With and Without Nephritis)
Idiopathic Inflammatory Myopathy
Systemic Sclerosis

Interventions

GENETIC: ALLO-329
DRUG: Cyclophosphamide

Sponsor

Allogene Therapeutics